(IN BRIEF) GSK has announced that China’s National Medical Products Administration has accepted for review a New Drug Application for bepirovirsen, an investigational antisense oligonucleotide designed to treat adults with chronic hepatitis B. The submission is supported by Phase III … Read the full press release
Posted in Healthcare, Marketing, Pharma & Biotech, Science, United Kingdom
Tagged antisense oligonucleotide, ASO therapy, B-Well 1 trial, B-Well 2 trial, Bepirovirsen, breakthrough therapy designation, CHB, China healthcare, chronic hepatitis B, clinical trials, drug development, functional cure, GSK Moves Closer to Transforming Chronic Hepatitis B Care with Bepirovirsen NDA Review in China, GSK plc, GSK Strengthens Infectious Disease Portfolio with Regulatory Submission for Novel Hepatitis B Therapy in China, HBsAg, hepatitis B surface antigen, infectious disease, liver cancer, National Medical Products Administration, NMPA, viral infection
(IN BRIEF) The University of Liverpool and Imperial College London, working with international partners, have published the first global systematic review of hepatitis B care, commissioned by WHO and covering over 1.7 million patients across 50 countries. The analysis found … Read the full press release
Posted in Business, Education, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Non Profit, Science, Technology, United Kingdom
Tagged Alexander Stockdale, antiviral therapy, chronic hepatitis B, decentralised healthcare, diagnosis gaps, global elimination target 2030, global health, Hepatitis B, HIV care models, Imperial College London, maternal health, partnership, Patient Retention, Philippa Easterbrook, postpartum care, primary care, The Lancet Gastroenterology & Hepatology, treatment initiation, University of Liverpool, WHO, World Health Organization
(IN BRIEF) GSK’s marketing authorisation application for linerixibat, an investigational ileal bile acid transporter inhibitor, has been accepted for review by the European Medicines Agency. The submission is supported by GLISTEN Phase III trial data showing that linerixibat rapidly and … Read the full press release
Posted in Business, Healthcare, Pharma & Biotech, United Kingdom
Tagged alcohol-related liver disease, bile acid transporter, cholestatic pruritus, chronic hepatitis B, EASL Congress, EMA, European Medicines Agency, FDA, GLISTEN trial, GSK, IBAT inhibitor, itch-related sleep interference, Kaivan Khavandi, linerixibat, Marketing Authorisation Application, MASH, NCT04950127, orphan drug designation, PBC, Phase III, primary biliary cholangitis, UK regulatory review
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?